<DOC>
	<DOCNO>NCT02726503</DOCNO>
	<brief_summary>The purpose phase â…¡ study ass efficacy safety lenvatinib anaplastic thyroid cancer patient diagnose unresectable . The total duration study 30 month . All patient start administration lenvatinib within 1 week enrollment receive study drug 24mg orally daily almost time . 1 cycle consist 4 week . Treatment term start day 1st drug administration cycle 1 administration continue patient meet withdrawal criterion . Safety efficacy assesment conduct regular basis trial . Tumor evaluation conduct 4weeks , 8 week , 12 week , 16 week every 8 week 16th week since initial administration . When study drug administration terminate , test drug termination conduct within 7 day withdrawal final observation conduct 30 day last dose . Survival survey conduct follow-up term . After termination study drug , survival follow survey conduct every 12 week unless patient withdraw enrollment study .</brief_summary>
	<brief_title>Phase II Study Assessing Efficacy Safety Lenvatinib Anaplastic Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Thyroid Carcinoma , Anaplastic</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>1 . Histologically confirm anaplastic thyroid cancer 2 . Unresectable disease 3 . Have measurable lesion define RECIST version 1.1 4 . Have adequate organ function meet follow laboratory value : 1 . Bone marrow function test within 14 day prior enrollment : neutrophil count &gt; =1.5 x 103/microL blood platelet count &gt; =10.0 x 104/microL hemoglobin amount &gt; =9.0 g/dL 2 . Liver function test within 14 day prior enrollment : AST , ALT &lt; =3.0 x ULN ( without liver metastatic ) AST , ALT &lt; =5.0 x ULN ( liver metastatic ) bilirubin &lt; =2.0 mg/dL 3 . Kidney function test within 14 day prior enrollment : GFR estimation &gt; =50 ml/min/1.73 m2 GFR estimation calculate follow formula . Male:194 x ( serum creatinine concentration ) 1.094 x ( Age ) 0.287 Female : Male GFR estimation x 0.739 4 . Cardiac function test within 28 day prior enrollment : 12lead electrocardiogram : clinically important abnormality show : heart disease , severe arrhythmia etc . 5 . Regardless usage antihypertensive drug , systolic blood pressure &lt; =140 mm Hg diastolic blood pressure &lt; =90 mm Hg ( If already take antihypertensive drug , must capacity antihypertensive therapy . ) 6 . ECOG performance status 02 7 . Ability swallow oral medication 8 . Life expectancy great 8 week 9 . Have sign write informed consent participate study 1 . Have complication medical history 1 . Complication brain metastasis ( Exclude cure clinically stable condition 1 month prior screen . ) 2 . Treatment required complication systemic infectious disease 3 . Complication pulmonary fibrosis interstitial pneumonitis 4 . Medical history clinically significant cardiovascular disease within 6 month initial dose : NYHA class 2 level congestive heart failure , unstable angina , cardiac infarction cardiac arrhythmia paroxysmal require treatment e ) Uncontrollable complication diabetes mellitus f ) hemoptysis within 3 week enrollment ( blood volume half teaspoon ) g ) Medical history hemorrhagic thrombotic disease within 6 month enrollment h ) If proteinuria value 2+ urinary protein qualitative test , conduct 24hour urine collection urine protein determine 1g/24 hour . ( substitute ratio proteinuria morning urine/creatinine ) ) Malabsorption gastrointestinal tract complication disease investigator considers affect lenvatinib absorption j ) Recent major surgery within 2 week ( needle biopsy within 1 week ) enrollment k ) Drainage require celomic fluid stagnation 2 . Have history lenvatinib administration 3 . Confirmed tumor invasion carotid arteries 4 . Have history high dose external radiation therapy cervical region , irradiated tumor location close carotid artery . 5 . Have unresolved toxicity great 1 CTCAE v4.0 . 6 . Have active double cancer 7 . Female patient pregnant , lactating , breast feeding childbearing potential 8 . Psychiatric disorder regard investigator inadequate study enrollment 9 . Confirmed resistance component drug 10 . Currently receive interventional clinical study treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>anaplastic thyroid cancer , lenvatinib</keyword>
</DOC>